FDA Warns about Potential Medication Errors 

Confusion Regarding Nonproprietary Name for Kadcyla (ado-trastuzumab emtasine)


Get Permission

The FDA recently alerted health-care professionals that the use of the incorrect nonproprietary name for the breast cancer drug Kadcyla (ado-trastuzumab emtansine, also known as T-DM1 during preapproval clinical trials) in some medication-related electronic systems poses a risk of mix-up with Herceptin (trastuzumab) and may result in medication errors. The dosing and treatment schedules for Kadcyla and Herceptin are quite different, and confusion between these products could lead to dosing errors and potential harm to patients.

The FDA-approved nonproprietary name for Kadcyla, ado-trastuzumab emtansine, should be used. However, some third-party publications, compendia references, health information systems (eg, electronic health record systems and systems used for pharmacy prescription processing, wholesaler ordering, pharmacy ordering, etc), and sites on the Internet have been incorrectly using the U.S. Adopted Name, which is “trastuzumab emtansine,” and omitting the “ado” prefix and hyphen. Use of this truncated version of Kadcyla’s nonproprietary name may cause confusion with Herceptin (trastuzumab).

FDA Recommendations

FDA recommends that health-care professionals should use both the FDA-approved proprietary (brand) name Kadcyla and its nonproprietary name (ado-trastuzumab emtansine) when communicating medication orders, on preprinted order sets, and in computerized order entry systems. Such redundancy may help to reduce the potential for medication errors. Additionally, strategies should be employed to warn against confusion between Kadcyla (ado-trastuzumab emtansine) and Herceptin (trastuzumab) in medication-related computer systems.

No medication errors related to confusion between Kadcyla and Herceptin have been reported to FDA since approval of Kadcyla on February 22, 2013. However, medication errors did occur during the clinical trials that evaluated its safety and efficacy prior to approval. ■



Advertisement

Advertisement



Advertisement